MGN 3

Drug Profile

MGN 3

Latest Information Update: 08 Apr 2003

Price : $50

At a glance

  • Originator Daiwa Pharmaceutical
  • Developer Daiwa Pharmaceutical; Lane Labs
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; HIV infections

Most Recent Events

  • 08 Apr 2003 No development reported - Phase-II for Cancer in USA (unspecified route)
  • 08 Apr 2003 No development reported - Preclinical for HIV infections treatment in USA (unspecified route)
  • 03 Apr 2001 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top